-
EP4265256
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4265256
| EP4265256 - USE OF PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.09.2023 Database last updated on 03.09.2024 | |
| Former | The international publication has been made Status updated on 25.06.2022 | Most recent event Tooltip | 11.05.2024 | Supplementary search report | published on 12.06.2024 [2024/24] | Applicant(s) | For all designated states Hung, Mien-Chie No. 91, Hsueh-Shih Road, North District Taichung City 404, Taiwan / TW | [2023/43] | Inventor(s) | 01 /
TSAI, Chang-hai Taichung City 404 / TW | 02 /
HUNG, Mien-chie Taichung City 404 / TW | 03 /
KUO, Sheng-chu Tainan City 700 / TW | 04 /
LEE, Pei-chih Taichung City 404 / TW | 05 /
HSIEH, Min-tsang Taichung City 420 / TW | 06 /
JUANG, Shin-hun Taipei City 111 / TW | 07 /
LIN, Hui-yi Taichung City 406 / TW | [2023/43] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2023/43] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 21905680.1 | 14.12.2021 | [2023/43] | WO2021CN137647 | Priority number, date | US202063126849P | 17.12.2020 Original published format: US 202063126849 P | [2023/43] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022127751 | Date: | 23.06.2022 | Language: | ZH | [2022/25] | Type: | A1 Application with search report | No.: | EP4265256 | Date: | 25.10.2023 | Language: | EN | [2023/43] | Search report(s) | International search report - published on: | CN | 23.06.2022 | (Supplementary) European search report - dispatched on: | EP | 10.05.2024 | Classification | IPC: | A61K31/121, A61P35/00, A61K31/538, A61K31/4439, A61K31/22, A61K31/506, A61K31/517, A61K31/5377, A61K45/06 | [2024/24] | CPC: |
A61K31/506 (EP,US);
A61K31/235 (KR);
A61K31/216 (US);
A61K31/121 (EP);
A61K31/22 (EP);
A61K31/517 (EP);
| C-Set: |
A61K31/121, A61K2300/00 (EP);
A61K31/22, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/517, A61K2300/00 (EP); |
| Former IPC [2023/43] | A61K31/538, C07D471/04, A61K31/4439, C07D498/04, A61P9/10, A61P35/04, A61P35/02 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/43] | Title | German: | VERWENDUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG ZUR BEHANDLUNG VON LUNGENKREBS | [2023/43] | English: | USE OF PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER | [2023/43] | French: | UTILISATION D'UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU CANCER DU POUMON | [2023/43] | Entry into regional phase | 14.07.2023 | Translation filed | 14.07.2023 | National basic fee paid | 14.07.2023 | Search fee paid | 14.07.2023 | Designation fee(s) paid | 14.07.2023 | Examination fee paid | Examination procedure | 14.07.2023 | Amendment by applicant (claims and/or description) | 14.07.2023 | Examination requested [2023/43] | Fees paid | Renewal fee | 14.12.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2017218219 (UNIV CHINA MEDICAL); |